Disease Domain | Count |
---|---|
Infectious Diseases | 3 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Unknown | 1 |
Peptide drug conjugates | 1 |
Target |
Mechanism RdRp inhibitors [+1] |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. GB |
First Approval Date14 Nov 2021 |
Mechanism Heparin agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Start Date01 Jul 2024 |
Sponsor / Collaborator |
Start Date01 May 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Molnupiravir ( RdRp ) | COVID-19 More | Phase 2 Clinical |
AWZ-1066-S ( Wolbachia ) | Onchocerciasis More | Preclinical |
Tafoxiparin ( Heparin x SARS-CoV-2 S protein ) | COVID-19 More | Preclinical |
RXPA380-P ( ACE ) | Hypertension More | Preclinical |
Filariasis Therapeutics (Eisai) | Filariasis More | Discovery |